<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953352</url>
  </required_header>
  <id_info>
    <org_study_id>19VADS01</org_study_id>
    <nct_id>NCT03953352</nct_id>
  </id_info>
  <brief_title>Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy</brief_title>
  <acronym>GIRAFE</acronym>
  <official_title>Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a prospective, monocentric study aiming to evaluate an adaptive radiotherapy&#xD;
      method (automatic deformable recontouring on the daily MVCT (MegaVoltage Computerized&#xD;
      Tomography)) using the Precise ART™ software in patients with head and neck cancer.&#xD;
&#xD;
      Patients will receive helical intensity-modulated radiotherapy (IMRT) according to the&#xD;
      standard recommendations (35 fractions during 7 weeks). Radiotherapy will include daily&#xD;
      repositioning MVCT.&#xD;
&#xD;
      For the study, patients will undergo 4 intermediate re-planning CT-scan (without injection of&#xD;
      intravenous contrast agent) at week 3, week 4, week 5 and week 6 of treatment.&#xD;
&#xD;
      3 recontouring modalities will be evaluated for the study:&#xD;
&#xD;
        -  Manuel recontouring (standard method)&#xD;
&#xD;
        -  Precise ART™ deformed contours&#xD;
&#xD;
        -  Precise RTX™ deformed contours&#xD;
&#xD;
      The total duration of the study for each patient will be 7 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study cancelled&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with Dice Similarity Coefficient (DSC) of the volumes of left and right parotid gland superior to 0.85 (DSC &gt; 0.85)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DSC &gt; 0.85 for other organs at risk (oral cavity, medullar canal, mandible,brain stem, larynx)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DSC &gt; 0.85 for target volumes (clinical target volume, gross target volume, planning target volume)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time saving defined by the difference between standard recontouring time (manuel recontouring) and experimental recontouring time (Precise ART™ or Precise RTX™)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Helical intensity-modulated radiotherapy (IMRT)</intervention_name>
    <description>Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.</description>
    <arm_group_label>Radiotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Patient with histologically proven locally advanced head and neck cancer (Oropharynx,&#xD;
             hypopharynx, larynx, nasopharynx, oral cavity, sinuses, nasal cavities, ethmoid sinus,&#xD;
             cavum, salivary glands)&#xD;
&#xD;
          3. Cancer with nodal involvement (at least T3 or involved node &gt;2 cm)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          5. No previous curative treatment for head and neck cancer (surgery and/or radiotherapy&#xD;
             and/or chemotherapy)&#xD;
&#xD;
          6. Indication of exclusive radiotherapy (+/- chemotherapy) validated in multidisciplinary&#xD;
             meeting&#xD;
&#xD;
          7. Patient affiliated to the french social security system.&#xD;
&#xD;
          8. Patient must provide written informed consent prior to inclusion in the study and any&#xD;
             study-specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with metastatic cancer&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group performance status ≥ 2 (due to comorbidities)&#xD;
&#xD;
          3. Patient with recurrent disease&#xD;
&#xD;
          4. Patient who required urgent surgical treatment&#xD;
&#xD;
          5. Contraindications to radiotherapy&#xD;
&#xD;
          6. History of cancer within 5 years&#xD;
&#xD;
          7. Patient already included in another therapeutic trial&#xD;
&#xD;
          8. Pregnant or breastfeeding women&#xD;
&#xD;
          9. Any psychological, familial, geographical or sociological condition potentially&#xD;
             preventing the medical follow-up and/or study procedures&#xD;
&#xD;
         10. Patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adaptive radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

